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OBJECTIVES The aim of the study was to test the hypothesis that leptin is involved in the regulation of
ventilatory responses to exercise in chronic heart failure (CHF).
BACKGROUND Exercise-induced hyperventilation is a negative prognostic factor in CHF. Studies in animals
suggest that leptin, a hormone secreted by adipocytes, contributes to the regulation of
respiration. Plasma leptin levels are elevated in non-cachectic CHF, suggesting the possibility
that leptin might be involved in dysregulation of ventilation in CHF.
METHODS We studied 50 patients with stable CHF without cachexia. All subjects underwent
anthropometric measurements, resting echocardiography, pulmonary function tests, and a
cardiopulmonary exercise test. The ventilatory response to exercise was assessed by calculating
the VE/VCO2 and VE/VO2 slopes (VE ventilation per unit time, VCO2 carbon dioxide
production, VO2  oxygen consumption).
RESULTS Using a multiple regression model, leptin was significantly and positively correlated with both
VE/VCO2 slope (regression coefficient  0.87, F  39.32, p  0.001) and VE/VO2 slope
(regression coefficient  0.84, F  24.04, p  0.001). This correlation was independent of
age, gender, body mass index, body fat, ejection fraction, New York Heart Association
functional class, pulmonary function, plasma norepinephrine, angiotensin II, brain natriuretic
peptide levels, and medications. Also, the greatest VE/VCO2 slope was seen in subjects in the
highest tertile of leptin.
CONCLUSIONS Leptin is an independent predictor of VE/VCO2 slope in heart failure, and may be a link
between metabolic, cardiovascular, and respiratory abnormalities in CHF. (J Am Coll
Cardiol 2003;42:1644–9) © 2003 by the American College of Cardiology Foundation
Leptin is a 167-amino-acid product of the ob gene, which is
produced primarily by adipocytes (1). Although originally
associated with the central regulation of satiety and energy
metabolism, there is now increasing evidence that leptin
may be an important mediator in cardiovascular pathophys-
iology (2–8). In addition, recent studies in animals suggest
that leptin may play an important role in the regulation of
respiration, particularly the ventilatory responses to CO2,
and may act both as a neurohumoral modulator of respira-
tory control mechanisms as well as by producing changes in
respiratory mechanics (9–13).
A growing body of literature has described marked
ventilatory abnormalities in response to exercise in chronic
heart failure (CHF), including a reduced ventilatory effi-
ciency (a high minute ventilation relative to metabolic
demand) (14). Ventilatory efficiency during exercise can be
assessed by calculating the VE/VCO2 slope, where VE 
ventilation per unit time and VCO2  carbon dioxide
production. Typically, the VE/VCO2 slope is increased in
patients with CHF in part due to an enhanced ventilatory
drive (15,16). Several recent studies have demonstrated that
a hyperventilatory response to exercise is a powerful prog-
nostic factor in CHF (15–19). When combined with
reduced peak oxygen consumption (VO2), ventilatory ab-
normalities identify a subgroup of CHF patients at a
particularly high risk of death (16,17,19). Importantly, the
VE/VCO2 slope may be a powerful predictor of event-free
survival, while peak VO2 does not substantially improve the
predictive value of the model (16,18). These latter observa-
tions speak to the pathophysiologic significance of the
mechanisms regulating ventilatory responses to exercise in
patients with CHF.
Most clinical studies have reported elevated circulating
leptin levels in non-cachectic CHF (20–24). However, the
pathophysiologic role of circulating leptin in CHF remains
unknown. In the present study we tested the hypothesis that
leptin is involved in the regulation of ventilatory responses
to exercise in subjects with CHF.
METHODS
Fifty consecutively eligible Caucasian patients with a diag-
nosis of stable non-cachectic systolic CHF were recruited
prospectively at the Mayo Clinic, Rochester, Minnesota.
Cardiac cachexia was defined as a body weight 85% of
ideal (25). The etiology of CHF was ischemic or nonisch-
emic dilated cardiomyopathy. Patients with conditions
likely to influence exercise tolerance independent of CHF
(primary lung disease, obesity, musculoskeletal diseases,
peripheral vascular disease, chest pain, pacemaker depen-
dency, atrial fibrillation), valvular heart disease, history of
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complex ventricular arrhythmias, or with a moderate smok-
ing history, were excluded. The clinical characteristics of the
study group are shown in Table 1. The study was approved
by the Mayo Institutional Review Board. Informed consent
was obtained before participation.
All subjects underwent anthropometric measurements
(including assessment of body fat [26]), resting echocardi-
ography, pulmonary function tests, and a cardiopulmonary
exercise test.
Left ventricular ejection fraction (EF) was assessed using
two-dimensional echocardiography. Pulmonary function
measurements were performed at rest and included an
assessment of forced vital capacity (FVC) and forced expi-
ratory volume in 1 s (FEV1). A single-breath diffusion
capacity of the lung for carbon monoxide (DLCO) was also
measured. Spirometry and DLCO data were collected in
accordance with the American Thoracic Society standards
(27).
Gas exchange was measured during graded treadmill
testing to volitional fatigue. The measurements were ob-
tained using a Medical Graphics metabolic cart validated
with classical gas collection techniques. An initial treadmill
speed and grade of 2 mph and 0%, respectively, were
adjusted every 2 min to yield 2 metabolic equivalent
increase per work level. Anaerobic threshold was deter-
mined by the V-slope method (28). Peak VO2 was defined
as the maximal oxygen uptake during exercise. Because of
the recent evidence that the adjustment of peak VO2 to lean
body mass increases its prognostic value and allows a more
reliable comparison between subjects with variable body
mass/fat (because body fat represents metabolically inactive
mass) (29), we also measured peak VO2 corrected for lean
body mass (lean peak VO2). The VE/VCO2 and VE/VO2
slopes were calculated below the respiratory compensation
point using linear regression analysis. The exercise charac-
teristics are shown in Table 2.
Blood samples were drawn at rest in a supine position.
Plasma norepinephrine was measured using high-
performance liquid chromatography (ESA Inc., Chelms-
ford, Massachusetts) (with inter- and intra-assay variability
of 3.4% and 3.1%, respectively) and plasma leptin was
measured by radioimmunoassay (Linco Research Inc., St.
Charles, Missouri) (intra- and inter-assay variability 3.4% to
8.3% and 3.6% to 6.2%, respectively). Brain natriuretic
peptide (BNP) was measured by immunoradiometric assay
(Shionogi and Co. Ltd., Osaka, Japan) (inter- and intra-
assay variability were both 8%) and angiotensin II was
measured using a nonequilibrium assay (Phoenix Pharma-
ceuticals, Belmont, California) (inter- and intra-assay vari-
ations were 13% and 9%, respectively).
Statistical analysis. In order to assess the independent
relationship between leptin and ventilation during exercise,
all variables were entered into a multiple stepwise regression
model. Peak VO2, VE/VO2 slope, and VE/VCO2 slope
were used as dependent variables. Independent variables
included age, gender, body mass index (BMI), body fat,
Abbreviations and Acronyms
BMI  body mass index
BNP  brain natriuretic peptide
CHF  chronic heart failure
DLCO  diffusion capacity of the lung for carbon
monoxide
EF  ejection fraction
FEV1  forced expiratory volume in 1 s
FVC  forced vital capacity
NYHA  New York Heart Association
VCO2  carbon dioxide production
VE  ventilation per unit time
VO2  oxygen consumption
Table 1. Clinical Characteristics (n  50)
Age (yrs) 55  11
Men (%) 66
Weight (kg) 84  18
BMI (kg/m2) 28  4
% body fat 28  6
Waist-to-hip ratio 0.9  0.1
NYHA functional class I/II/III (n) 19/22/9
EF (%) 28  10
Leptin (ng/ml) 11  8
Norepinephrine (pg/ml) 388  246
Angiotensin II (pg/ml) (n  42) 15  14
BNP (pg/ml) (n  46) 424  685
Creatinine (mg/dl) (n  47) 1.4  0.6
% pred FVC 89  15
% pred FEV1 87  16
% pred DLCO 92  16
Medical history (%)
Myocardial infarction 10
Hypertension 24
Hyperlipidemia 44
Diabetes 14
Medications (%)
ACE inhibitors/AT receptor blockers 92
Beta-blockers 62
Digoxin 68
Diuretics 62
Data are expressed as mean  SD.
ACE  angiotensin-converting enzyme; AT  angiotensin; BMI  body mass
index; BNP  brain natriuretic peptide; DLCO  diffusion capacity for carbon
monoxide; EF  ejection fraction; FEV1  forced expiratory volume in 1 s; FVC 
forced vital capacity; NYHA  New York Heart Association.
Table 2. Exercise Characteristics (n  50)
Exercise time (min) 7.8  2.7
Rest systolic blood pressure (mm Hg) 113  20
Rest diastolic blood pressure (mm Hg) 73  13
Rest heart rate (beats/min) 74  13
Peak systolic blood pressure (mm Hg) 145  38
Peak diastolic blood pressure (mm Hg) 73  22
Peak heart rate (beats/min) 136  26
Total peak VO2 (ml/kg/min) 20  6
Lean peak VO2 (ml/kg/min) 28  8
VE/VCO2 slope 27  5
VE/VO2 slope 26  6
Data are expressed as mean  SD.
VCO2  carbon dioxide production; VE  ventilation per unit time; VO2 
oxygen consumption.
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waist-to-hip ratio, New York Heart Association (NYHA)
functional class, EF, plasma norepinephrine, angiotensin II
and BNP levels, % predicted FVC, % predicted FEV1, %
predicted DLCO, and leptin. After the initial analysis,
medications were added to the model. A value of p  0.05
was considered significant.
RESULTS
In univariate analysis, leptin was related to VE/VCO2 slope
(Table 3), VE/VO2 slope (r  0.49, p  0.001), and lean
peak VO2 (Table 4). Leptin was also positively correlated
with female gender (r  0.37, p  0.008), BMI (r  0.51,
p  0.001), and body fat (r  0.73, p  0.001), and
negatively correlated with % predicted FVC (r  0.29, p
 0.038), % predicted FEV1 (r  0.28, p  0.045), and
% predicted DLCO (r  0.32, p  0.022). Apart from
the correlation with leptin, VE/VCO2 slope was also
positively correlated with age, plasma norepinephrine, and
BNP, and negatively correlated with the respiratory func-
tion tests (Table 3). The VE/VCO2 slope did not correlate
with body fat in univariate analysis. However, the relation-
ship between leptin and VE/VCO2 slope was further
strengthened when leptin levels were adjusted for body fat (r
 0.50, p  0.001).
When plasma leptin levels were divided into tertiles, the
greatest VE/VCO2 slope was seen in subjects in the highest
tertile of leptin (Fig. 1a). In contrast, there was no difference
between VE/VCO2 values in patients divided into tertiles of
body fat (Fig. 1b).
In previous publications the threshold value for VE/
VCO2 slope of 34 was used and shown to identify CHF
patients at an increased risk of death (15,19). In our study
seven subjects had VE/VCO2 slopes 34. In those subjects
leptin levels were higher compared with the rest of the study
group, both when expressed in absolute values (18.0  10.7
ng/ml vs. 10.3 7.6 ng/ml; p 0.022) and when expressed
as leptin-to-body fat ratio (0.60  0.32 vs. 0.34  0.20; p
 0.004).
In multivariate analysis, leptin was no longer associated
with lean peak VO2 (Table 4), but remained significantly
correlated with both VE/VCO2 slope (Table 3) and VE/
VO2 slope (regression coefficient  0.84, F  24.04, p 
0.001). The positive correlation between leptin and venti-
latory responses to exercise was independent of age, gender,
NYHA functional class, BMI, body fat (expressed as %
body fat or absolute fat mass), EF, plasma angiotensin II
and BNP levels, or resting pulmonary function. Consistent
with previous reports (30), VE/VCO2 slope was related to
plasma norepinephrine levels, but the association with leptin
was independent of norepinephrine. Importantly, VE/
VCO2 slope was significantly and independently correlated
not only with absolute levels of leptin, but also with leptin
adjusted for body fat (regression coefficient  0.84, F 
38.61, p  0.001), body weight (regression coefficient 
0.78, F  29.19, p  0.001), and BMI (regression coeffi-
cient 0.77, F 31.58, p 0.001). It should be noted that
in multivariate analysis and independent of leptin levels,
body fat was a negative predictor of ventilatory responses to
exercise.
When medication (angiotensin-converting enzyme in-
hibitors and angiotensin receptor blockers, beta-blockers,
digoxin, and diuretics, each as a separate independent
Table 3. Association Between VE/VCO2 Slope and
Independent Variables in Univariate and Multivariate Analysis
Univariate
Multivariate
(Stepwise Regression)
r p Beta-Coefficient F Ratio p
Age (yrs) 0.32 0.026 0.30 9.91 0.003
Female gender 0.02 NS 0.24 4.41 0.042
BMI 0.04 NS
Body fat (%) 0.05 NS 0.75 21.75 0.001
Waist-to-hip
ratio
0.07 NS
NYHA class 0.21 NS
EF (%) 0.20 NS
Leptin (ng/ml) 0.44 0.001 0.87 39.32 0.001
Norepinephrine
(pg/ml)
0.31 0.028 0.21 4.83 0.033
Angiotensin II
(pg/ml)
0.20 NS
BNP (pg/ml) 0.32 0.029 0.20 4.52 0.039
% pred FVC 0.31 0.029
% pred FEV1 0.27 0.063
% pred DLCO 0.29 0.042
Blank spaces indicate the variables removed during the stepwise regression process.
Beta-coefficient: standardized regression coefficient representing the independent
correlation between the respective variable and the dependent variable (after control-
ling for all other independent variables studied).
Abbreviations as in Table 1.
Table 4. Association Between Lean Peak VO2 and Independent
Variables in Univariate and Multivariate Analysis.
Univariate
Multivariate
(Stepwise Regression)
r p Beta-Coefficient F Ratio p
Age (yrs) 0.30 0.037 0.46 14.88 0.001
Female gender 0.05 NS
BMI 0.14 NS
Body fat (%) 0.06 NS
Waist-to-hip
ratio
0.18 NS
NYHA class 0.29 0.041
EF (%) 0.37 0.008 0.41 17.04 0.001
Leptin (ng/ml) 0.29 0.043
Norepinephrine
(pg/ml)
0.24 NS 0.27 6.98 0.016
Angiotensin II
(pg/ml)
0.12 NS
BNP (pg/ml) 0.33 0.025
% pred FVC 0.32 0.024
% pred FEV1 0.27 0.054
% pred DLCO 0.31 0.027 0.37 11.62 0.002
Blank spaces indicate the variables removed during the stepwise regression process.
Beta-coefficient: standardized regression coefficient representing the independent
correlation between the respective variable and the dependent variable (after control-
ling for ll other independent variables studied).
Abbreviations as in Table 1.
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variable) entered the model, leptin was still independently
associated with VE/VCO2 slope (beta-coefficient  0.92, F
 47.83, p  0.001) and VE/VO2 slope (beta-coefficient 
0.46, F  18.06, p  0.001).
We also investigated whether leptin levels were correlated
with ventilatory responses during exercise after adding lean
peak VO2 (an index of the severity of heart failure) to the
model as an independent variable. Although lean peak VO2
was significantly (negatively) correlated with ventilatory
responses to exercise in multivariate analysis, leptin still
remained an independent predictor of VE/VCO2 slope
(beta-coefficient  0.75, F  29.64, p  0.001) and
VE/VO2 slope (beta-coefficient  0.36, F  9.78, p 
0.003).
DISCUSSION
The novel finding of the present study is the independent
relationship between plasma leptin levels and ventilatory
responses to exercise in non-cachectic patients with CHF.
Specifically, we show that there is a positive correlation
between resting plasma leptin levels and VE/VCO2 slope
during exercise, which cannot be explained on the basis of
anthropometric measurements, body fat, EF, peak VO2,
other neurohormone levels, pulmonary function tests, or
medication. That plasma leptin is not affected by acute
exercise (31,32) supports the possibility that leptin levels
measured at rest in our study may be directly related to the
regulation of ventilation also during exercise.
Leptin circulates not only in its free form, but also in a
complexed form, with the soluble leptin receptor being the
major leptin-binding protein (33). Therefore, a possible
limitation of our study is the fact that we did not measure
plasma levels of the soluble leptin receptor. However, the
physiologic role of the soluble leptin receptor has not yet
been clarified, either in humans or in animal models. On the
one hand, it is possible that the circulating leptin receptor
binds leptin and acts as an inhibitor of its biologic effects.
On the other hand, the soluble leptin receptor may delay
leptin clearance in the kidney leading to hyperleptinemia.
The bound leptin may then be made available for release
and activate leptin responses. In addition, the soluble leptin
receptor may play a role in the transport of leptin across the
blood-brain barrier, thereby modulating the effects of leptin
in the central nervous system. Consistent with this mode of
action, an increase in circulating leptin and an increased
weight-reducing effect of leptin were both observed in mice
overexpressing the soluble leptin receptor (34). Taken to-
gether, these observations suggest that, although the soluble
leptin receptor may regulate leptin’s availability and bioac-
tivity, its actual role is still unknown and it may potentially
either increase or decrease the effects of leptin. Further
studies are needed to clarify this issue before the measure-
ments of the soluble leptin receptor can be unambiguously
interpreted.
The mechanisms underlying enhanced VE/VCO2 slope
in CHF are complex and probably multifactorial. Several
explanations have been proposed, including abnormalities of
pulmonary hemodynamics and increased pulmonary dead
space (35–38), ergoreceptor overactivity (39), and abnor-
malities of ventilatory reflex control (40,41). With respect to
the latter mechanism, it has been reported that an abnor-
mally elevated VE/VCO2 slope in CHF correlates with
both central and peripheral chemosensitivity (40,41). Inter-
estingly, this relationship was much stronger for central
hypercapnic chemosensitivity (40,41). This observation is in
agreement with our previous study, which demonstrated a
selective potentiation of central chemosensitivity in patients
with stable CHF (42).
The effects of leptin on the above mechanisms are
essentially unknown. An intriguing possibility is the effect of
Figure 1. Relationship between VE/VCO2 slope and nonadjusted leptin
levels (a) and body fat (b) divided into tertiles (analysis of variance
[ANOVA], followed by Newman-Keuls multiple comparison post-hoc
tests). Data are expressed as mean SEM. When leptin levels adjusted for
body fat were divided into tertiles, the relationship between the adjusted
leptin tertiles and VE/VCO2 slope was virtually identical to that between
VE/VCO2 slope and unadjusted leptin. VCO2  carbon dioxide produc-
tion; VE  ventilation per unit time.
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leptin on ventilatory control. The influence of leptin on
pulmonary mechanics (12) seems unlikely as an explanation
for our findings, because in our study the effects of leptin
were independent of pulmonary function. It is of note,
however, that studies in ob/ob mutant mice have demon-
strated that leptin is a powerful respiratory stimulant and
leptin deficiency is associated with a depressed hypercapnic
ventilatory response (9,13). Leptin replacement in animals
with respiratory depression and elevated PaCO2 has been
shown to reverse hypoventilation, most likely by stimulation
of central respiratory control centers (11). These studies in
animals are consistent with the observation that chemoreflex
sensitivity to CO2 is selectively potentiated in human
obesity (a condition known to be associated with elevated
leptin levels) (43). Although significant hypercapnia is not
usually seen during exercise, this does not exclude the
presence of increased chemosensitivity, whereby a given
CO2 level would constitute a stronger ventilatory stimulus.
Nevertheless, other mechanisms underlying the association
between leptin and ventilation during exercise may also be
important and require further studies.
Although age, female gender, norepinephrine, BNP,
leptin, and body fat were all associated with VE/VCO2
slope in multivariate analysis, leptin and body fat were by far
the most powerful predictors. The strong negative associa-
tion between body fat (whether expressed as % body fat or
fat mass) with ventilation during exercise is of interest. This
association was independent of leptin, BMI, or fat distri-
bution, and opposite to the effects of leptin (Table 3),
suggesting that body fat (perhaps through some other, as yet
unidentified mechanisms) exerts an inhibitory and leptin-
independent influence on ventilation during exercise. The
benchmark clinical studies, which established the relation-
ship between VE/VCO2 slope and prognosis in heart
failure, did not take body fat into account (15–19). Our
results showing an inverse correlation between body fat and
VE/VCO2 slope, after adjusting for leptin, are consistent
with emerging data suggesting an inverse relationship be-
tween indices of obesity and clinical outcome in patients
with heart failure (44–46).
Leptin has been recently shown to be an independent risk
factor for coronary heart disease (47). Elevated VE/VCO2
slope is an important predictor of prognosis in CHF
(15–19). The association between leptin and VE/VCO2
slope may thus conceivably contribute, at least in part, to the
negative prognostic associations of increased VE/VCO2
slope. Our findings suggest a novel concept in heart failure
pathophysiology, namely that leptin, independent of obe-
sity, may be a link between metabolic, cardiovascular, and
respiratory abnormalities in CHF.
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